We would like to welcome Liselotte Hyveled to our Board, who joins us with extensive experience with the entire drug development value chain, primarily from her role as Project Vice President in Novo Nordisk A/S. Her strong background within the fields of Diabetes, Haematology, Hormone Replacement Therapy and Trauma, specifically as it relates to working with regulatory agencies such as EMA, PMDA and FDA, will be of great benefit to RSP Systems.
M.Sc. (Pharm) from Copenhagen University and a Master of Medical Business Strategies from Copenhagen Business School
She will be joining a group of other distinguished members of the board who include: Jens U. Holst, Georg von Werz, Roland Berger, Robert von Werz, Jacob Philipsen, and Michael Obermayer.